Advancements in health research.
Loading your page…
Loading your page…
Advancements in health research.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
Introduction. Tirzepatide is indicated, in combination with calorie restriction and physical activity, for the treatment of obesity and overweight with weight-related comorbidities. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine in adults with at least four migraine days per month (1,2). Evidence regarding the safety of the concomitant use of these two drugs is currently scarce.Methods. We conducted a preliminary observational case series including five non-diabetic women aged 35–45 years with migraine without aura and obesity (BMI 30–32 kg/m²). All patients had been receiving atogepant 60 mg once daily for at least one month before starting tirzepatide. Tirzepatide was initiated at 2.5 mg subcutaneously once weekly and increased to 5 mg weekly after four weeks according to routine clinical practice. Patients were followed jointly by a Headache Center and a dietitian while adhering to a hypocaloric diet and regular physical activity. The primary endpoint was the clinical safety of the drug combination. Secondary outcomes included changes in migraine-related disability assessed using the MIDAS questionnaire.Results. No clinically relevant adverse events attributable to the concomitant administration of atogepant and tirzepatide were observed during follow-up. No patient discontinued treatment because of adverse events. The combination was well tolerated in all five patients. Progressive body weight reduction was observed in all subjects. Migraine-related disability improved or remained stable after tirzepatide initiation, with MIDAS grades improving from baseline in all patients. No clinical findings suggested pharmacological interactions between the two therapies.Conclusions. In this preliminary case series, the concomitant administration of atogepant and tirzepatide showed a favorable short-term safety profile, with no emerging safety signals or treatment-limiting adverse events. Both therapies maintained their expected clinical effectiveness during combined administration. Although these findings are encouraging, the small sample size, short follow-up, and absence of a control group preclude definitive conclusions. Larger prospective studies are warranted to better define the safety profile of this pharmacological association.
Published in Advancements in health research.. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.